3-ethyl-5-(1-methyl-1H-pyridin-2-ylidene)-2-thioxothiazolidine-4-one | 36772-64-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-ethyl-5-(1-methyl-1H-pyridin-2-ylidene)-2-thioxothiazolidine-4-one
• 英文别名: Einecs 253-200-7；(5Z)-3-ethyl-5-(1-methylpyridin-2-ylidene)-2-sulfanylidene-1,3-thiazolidin-4-one
• CAS: 36772-64-2
• 化学式: C₁₁H₁₂N₂OS₂
• 分子量: 252.361
• InChiKey: HLIACYSTIJITSD-HJWRWDBZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  80.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-ethyl-5-(1-methyl-1H-pyridin-2-ylidene)-2-thioxothiazolidine-4-one 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 3.0h， 生成 Toluene-4-sulfonate2-[3-ethyl-5-[1-methyl-1H-pyridin-(2Z)-ylidene]-4-oxo-thiazolidin-(2Z)-ylidenemethyl]-1-methyl-pyridinium;
  参考文献：
  名称：

  Rhodacyanine Dyes as Antimalarials. 1. Preliminary Evaluation of Their Activity and Toxicity

  摘要：

  The rhodacyanine dye MKT-077 (1), a potent antitumor agent, was found to possess strong in vitro activity against Plasmodium falciparum and a low cytotoxicity. Several new rhodacyanine dyes related to 1, containing a variety of linked heterocyclic moieties, were synthesized, and their antimalarial potencies were evaluated. The synthetic rhodacyanines were found to have EC50 values against P. falciparum in vitro in the range of 4-300 nM. Several compounds in this series have remarkable selective toxicity profiles (> 100).

  DOI：

  10.1021/jm0155704
• 作为产物：
  描述：

  2-甲硫基吡啶 在 三乙胺 作用下， 以 苯甲醚 、 乙腈 为溶剂， 反应 2.5h， 生成 3-ethyl-5-(1-methyl-1H-pyridin-2-ylidene)-2-thioxothiazolidine-4-one
  参考文献：
  名称：

  Rhodacyanine Dyes as Antimalarials. 1. Preliminary Evaluation of Their Activity and Toxicity

  摘要：

  The rhodacyanine dye MKT-077 (1), a potent antitumor agent, was found to possess strong in vitro activity against Plasmodium falciparum and a low cytotoxicity. Several new rhodacyanine dyes related to 1, containing a variety of linked heterocyclic moieties, were synthesized, and their antimalarial potencies were evaluated. The synthetic rhodacyanines were found to have EC50 values against P. falciparum in vitro in the range of 4-300 nM. Several compounds in this series have remarkable selective toxicity profiles (> 100).

  DOI：

  10.1021/jm0155704

文献信息

• Structure of rhodanine cyanine dyes, spectroscopy and performance in photographic emulsions
  作者：Zheng-Hong Peng、Xiang-Feng Zhou、Suzanne Carroll、Herman J. Geise、Bi-xian Peng、Roger Dommisse、Eddy Esmans、Robert Carleer

  DOI：10.1039/jm9960601325

  日期：——

  The synthesis is reported of eight pyridine–, benzothiazole– and benzimidazole–rhodanine zeromethine merocyanines as blue–sensitising dyes (1–8), and of three benzoxazole-rhodanine dimethine merocyanines as green-sensitising dyes (9–11). The compounds were characterised from UV–VIS, mass spectroscopic and NMR data, and the purity of the products was analysed using HPLC. Oxidation potentials were measured using cyclic voltammetry. Ionisation potentials and electron affinities were obtained by semi-empirical MOPAC calculations. The charge-density distributions of the pyridine and benzothiazole rhodanine dyes are in agreement with assignments in NMR spectroscopy. A linear dependence is found between the oxidation potential and ionisation potential, as well as between the reduction potential and electron affinity. Reflection spectra of 6 and 7 coated on photographic emulsions showed J-aggregate absorption at λ= 450 and 465 nm, respectively. The sensitising properties of the merocyanine dyes were evaluated in actual photographic T-grain emulsions.

  报告了 8 种作为蓝色敏化染料的吡啶、苯并噻唑和苯并咪唑-罗丹宁零甲胺美拉德花青素（1-8）和 3 种作为绿色敏化染料的苯并恶唑-罗丹宁二甲胺美拉德花青素（9-11）的合成。根据紫外可见光谱、质谱和核磁共振数据对这些化合物进行了表征，并使用高效液相色谱分析了产品的纯度。使用循环伏安法测量了氧化电位。电离电位和电子亲和力是通过半经验 MOPAC 计算获得的。吡啶和苯并噻唑罗丹宁染料的电荷密度分布与核磁共振光谱的分配一致。氧化电位和电离电位之间以及还原电位和电子亲和力之间呈线性关系。涂在感光乳剂上的 6 和 7 的反射光谱显示，在 λ= 450 和 465 纳米处分别有 J-聚集吸收。在实际的照相 T 粒乳剂中对梅洛菁染料的敏化特性进行了评估。
• Structure−Activity of Novel Rhodacyanine Dyes as Antitumor Agents
  作者：Masayuki Kawakami、Keizo Koya、Toshinao Ukai、Noriaki Tatsuta、Akihiko Ikegawa、Keizo Ogawa、Tadao Shishido、Lan Bo Chen

  DOI：10.1021/jm970590k

  日期：1998.1.1

  We have previously reported that rhodacyanine dyes, such as 1 and 2, exhibited a potent inhibitory effect on the growth of several tumor cells and that 4-oxothiazolidine (rhodanine) was an essential moiety for antitumor activity. On the basis of our foregoing work, two types of rhodacyanine dyes, which categorized into class I and II depending on the methine length, were synthesized and evaluated as a novel antitumor agent. Attention was particularly focused on the structure-activity study of two heteroaromatic rings. In class I, where the A rings were conjugated to rhodanine via two methine groups, compounds 1, 20, 23, and 24 were found to be efficacious in tumor-bearing nude mice model study, but they did not have the chemical properties (stability, solubility) suitable for clinical use. In contrast, in class II, where the A rings were directly conjugated to rhodanine, compounds 13 and 25, which possessed a benzothiazole moiety for the A ring, exhibited the favarable biological and chemical properties. Therefore, we decided to have a benzothiazole moiety as the A ring and introduce various heterocyclic groups for the B ring. As a result, the pyridinium ring was selected as the optimal moiety for the B ring (compound 13). Further, the variation of counteranion had a profound effect on solubility in water without influence on antitumor activity. Chloride anion was selected as the favorable anion with respect to synthetic method as well as solubilty in water. Our study finally led us to the identification of compound 3 (MKT 077, 1-ethyl-2-[[3-ethyl-5-(methylbenzothiazolin-2-ylidene)-4-oxothiazolidin-2-ylidene]methyl]pyridinium chloride) as the candidate for clinical trials and is currently subjected to further investigation as a potent antitumor agent in phase I clinical trial for the treatment of solid tumors.
• WO2006/137258
  申请人：——

  公开号：——

  公开（公告）日：——
• PHARMACEUTICAL COMPOSITION COMPRISING AZARHODACYANINE COMPOUND AS ACTIVE INGREDIENT
  申请人：Ihara Masataka

  公开号：US20090076067A1

  公开（公告）日：2009-03-19

  The object of the invention is to provide pharmaceutical composition that can be used as a therapeutic and/or prophylactic agent. Particularly, the pharmaceutical composition of the invention has significant therapeutic effect and survival benefit for the disease caused by parasitic protozoa, and selective toxicity against the causative protozoa. The pharmaceutical composition comprises a compound represented by general formula (1). Particularly, the invention relates to a composition that is an effective therapeutic/prophylactic agent for malaria, leishmania, African sleeping sickness, Chagas disease, toxoplasmosis lymphatic filariasis, babesiosis, and coccidiosis, and a novel compound contained therein.